American Express is defending its high interchange fees in court against claims by the US Department of Justice that those fees harm competition, according to reports.
AmEx president of the company’s US consumer services business Joshua Silverman testified in court this week to defend those high fees, arguing that they are crucial to the credit card company’s unique rewards program, which gives AmEx its competitive edge over rivals.
Being forced to lower those fees “would be disastrous, and we would have to rethink everything in our business model,” Silverman told US District Judge Nicholas Garaufis on Monday.
But the DOJ claims that those fees harm competition because they impose unfair rules on merchants that block those merchants from encouraging customers to use credit cards with lower swipe fees like Visa and MasterCard.
But American Express says that its top rivals Visa and MasterCard are too big to be harmed by AmEx’s merchant agreements. According to the company, Visa and MasterCard hold a combined 1 billion cards in the country; AmEx, in comparison, has about 55 million.
According to reports, the DOJ’s suit against AmEx is the first time a credit card company has faced trial on allegations that swipe-fee rules violate antitrust law.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan